Contineum Therapeutics (CTNM) Other Non-Current Liabilities (2023 - 2024)
Contineum Therapeutics (CTNM) posted quarterly Other Non-Current Liabilities of $228000.0 for Q1 2024, up 107.27% quarter-over-quarter from $110000.0 in Q4 2023.
Powered by 
Analysis
Contineum Therapeutics (CTNM) Other Non-Current Liabilities (2023 - 2024) Analysis & Trends
Contineum Therapeutics' Other Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $228000.0 for Q1 2024.
- In Q1 2024, Other Non-Current Liabilities changed N/A year-over-year to $228000.0; the TTM figure through Mar 2024 stood at $228000.0 (changed N/A YoY), while the FY2023 annual figure was $110000.0, changed N/A from the prior year.
- Other Non-Current Liabilities for Q1 2024 stood at $228000.0, up from $110000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $228000.0 in Q1 2024, with the low at $110000.0 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 10 | Contineum Therapeutics | 619.34 Mn | 619.34 Mn | - |